PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsDeutetrabenazine
Deutetrabenazine
Austedo (deutetrabenazine) is a small molecule pharmaceutical. Deutetrabenazine was first approved as Austedo on 2017-04-03. It is used to treat chorea and tardive dyskinesia in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Austedo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Deutetrabenazine
Tradename
Company
Number
Date
Products
AUSTEDO XRTevaN-216354 RX2023-02-17
8 products, RLD, RS
AUSTEDOTevaN-208082 RX2017-04-03
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
austedoNew Drug Application2022-05-17
austedo austedo xrNew Drug Application2024-07-01
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration
Code
DEUTETRABENAZINE, AUSTEDO, TEVA BRANDED PHARM
2024-12-24PED
2024-10-03PED
2024-06-24M-54
2024-04-03ODE-134
Patent Expiration
Patent
Expires
Flag
FDA Information
Deutetrabenazine, Austedo Xr, Teva
113114882041-06-10DPU-1995, U-3055
Deutetrabenazine, Austedo, Teva Branded Pharm
111793862038-03-15DPU-1995, U-3055
118132322038-03-15DP
109599962036-03-07U-3055
113577722036-03-07U-1995, U-3055
114462912036-03-07U-1995
115649172036-03-07U-1995
116482442036-03-07U-1995
92339592033-09-18DP
92967392033-09-18DP
95507802033-09-18DS, DPU-1995, U-3055
98147082033-09-18DP
116665662033-09-18DP
85247332031-04-03DS, DP
ATC Codes
N: Nervous system drugs
— N07: Other nervous system drugs in atc
— N07X: Other nervous system drugs in atc
— N07XX: Other nervous system drugs in atc
— N07XX16: Deutetrabenazine
HCPCS
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Huntington diseaseD006816Orphanet_399G10213——5
Tourette syndromeD005879EFO_0004895F95.2113——4
SyndromeD013577——113——4
DyskinesiasD020820HP_0002310G24—14——4
Tardive dyskinesiaD000071057—G24.01—13——3
ChoreaD002819EFO_0004152G25.5——2——2
Cerebral palsyD002547—G80——2——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Dystonic disordersD020821—G2411———1
DystoniaD004421HP_0001332G2411———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDeutetrabenazine
INNdeutetrabenazine
Description
Austedo (dutetrabenazine) is a small molecule pharmaceutical. Dutetrabenazine was first approved as Austedo on 2017-04-03.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
[2H]C([2H])([2H])Oc1cc2c(cc1OC([2H])([2H])[2H])C1CC(=O)C(CC(C)C)CN1CC2
Identifiers
PDB—
CAS-ID1392826-25-3
RxCUI—
ChEMBL IDCHEMBL3137326
ChEBI ID—
PubChem CID45255840
DrugBank—
UNII IDP341G6W9NB (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Austedo – Teva
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
No data
Safety
Black-box Warning
Black-box warning for: Austedo, Austedo austedo xr
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,754 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use